Haribo recalls ‘Happy Cola' sweets in Netherlands after cannabis found
A shopper looks at Haribo candies from Germany at Economy Candy in New York City on April 4, 2025. (Richard Drew / AP Photo)
The HAGUE, Netherlands -- Haribo recalled its 'Happy Cola' sweets in the Netherlands on Thursday after cannabis was discovered in the packets and several people, including children, fell ill.
The Dutch Food and Consumer Product Safety Authority (NVWA) said only three bags of the 'Happy Cola F!ZZ' were affected but a complete recall was undertaken as a precaution.
'There are bags in circulation with sweets that can lead to health complaints, such as dizziness, when consumed,' said the NVWA in a statement.
NVWA spokesperson Saida Ahyad told AFP: 'Cannabis was found in the cola bottles in question,' referring to the sweets' shape.
'The police reported this to the NVWA after several people, both children and adults, became ill after eating the cola bottles.'
Ahyad said police were now investigating how the cannabis made its way into the sweet bags.
'After consultation with the NVWA and as is customary in these types of situations, Haribo has issued a safety warning,' said Ahyad.
'Do not eat the sweets,' warned the NVWA.
Patrick Tax, marketing vice-president at Haribo, said the product recall concerned 'a limited number of cases' with one product in the east of the country.
'The safety of our consumers is our highest priority and Haribo takes this incident very seriously,' Tax said in a statement sent to AFP.
'This is a live issue and we are working closely with the Dutch authorities to support their investigation and establish the facts around the contamination,' he added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
Watch for kids, buses and don't ‘overshare': OPP
A message from OPP Commissioner Thomas Carrique reminding everyone to have a safe Labour Day long weekend and start of the school year. It is that time of year once again when children are heading back to school and numerous big yellow vehicles will return to the road. To that end, police in northeastern Ontario are reminding both parents and drivers to be safe. Back to school backpacks New backpacks line the hallways at Queen Elizabeth II Public School on the first day back to school. September 6, 2022. (File photo/Chelsea Papineau/CTV New Northern Ontario) Drivers In a news release on Friday, the Ontario Provincial Police (OPP) reminded drivers to keep their eyes on the road and 'not on (their) phone.' Police said to watch for young people walking or biking to and from school and to be prepared for school buses to make frequent stops. The OPP offered the following tips to drivers for the as students return to class: Flashing yellow lights on a school bus means it is preparing to stop, red flashing lights and the stop arm extended mean you must stop, give school buses extra room on the roadway, slow down and use extra caution when traveling through school zones and watch for and obey crossing guards. 'Passing a stopped school bus, with its red lights flashing, puts young lives at risk and means a fine of $400 to $2,000 and six demerit points for a first offence,' said police. School bus Parents Police also reminded parents to remind their children about safety rules when it comes to getting on and off buses, or to always use sidewalks and crosswalks if they are available. School bus Social Media 'Those first-day pics are great to share with family and friends on social media, but criminals can use the opportunity to harvest information from these posts,' the OPP said. Police provided the following tips to 'play it safe' on social media: Remove any mention of a particular school Remove all age and grade information Ensure your privacy settings are set properly Ensure your posts are only being shared with friends you know 'Let's all accept the shared responsibility to make the beginning of the school year a safe and fun event,' said OPP regional media relations coordinator Bill Dickson.
Globe and Mail
4 hours ago
- Globe and Mail
Bristol Myers Collaborates With BNTX for Oncology Candidate
BMY announced a strategic collaboration agreement with BioNTech BNTX. Both companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327 is a novel investigational bispecific antibody combining two complementary, validated mechanisms in oncology into a single molecule. Shares of BNTX surged on the deal announcement. Shares of Bristol Myers lost 12.8% year to date compared with the industry 's decline of 2.2%. More on BMY & BNTX Agreement Per the terms, BMY and BNTX will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products. Both BMY and BNTX own the right to develop BNT327 independently in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BNTX will also receive $2 billion in non-contingent anniversary payments through 2028. BioNTech is also eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones. Both the companies will jointly share development and manufacturing costs along with profits on an equal basis. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. It is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date, including phase III studies with registrational potential evaluating BNT327 as first-line treatment in extensive stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). A phase III study evaluating the candidate in triple negative breast cancer (TNBC) is planned to start by the end of 2025. Data from ongoing trials (on a preliminary basis) underscore the potential for combining anti-PD-L1 and anti-VEGF-A – two well-established therapeutic targets – into a single molecule to deliver synergistic clinical benefits for patients across multiple tumor types. BMY Looks to Diversify Business BMY is depending on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition. BMY earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy. The approval broadens BMY's portfolio. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY's top line in the coming years. BMY has experienced a few pipeline setbacks in recent months, which negatively impacted its share price. The late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy did not meet its dual primary endpoints. The top-line results from the phase III ARISE study on schizophrenia drug Cobenfy were also disappointing. The study is evaluating the efficacy and safety of the drug as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment. In November, Merck signed a deal with China-based LaNova Medicines for the latter's PD-1xVEGF targeting bispecific antibody candidate, LM-299. The latest entrant into this space is Pfizer PFE, which recently entered a multi-billion-dollar deal with Chinese biotech 3SBio for the latter's PD-1/VEGF bispecific antibody SSGJ-707. The deal is expected to be complete in third-quarter 2025. BMY's Zacks Rank & Stocks to Consider Bristol Myers currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Pfizer, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.47 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.02 during this timeframe. The stock has risen 18.6% so far this year. Pfizer's 2025 EPS estimate has risen from $2.97 to $3.06 in the past 60 days, while that for 2026 has gone up from $2.99 to $3.09 over the same timeframe. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
Globe and Mail
5 hours ago
- Globe and Mail
Bachem Mourns the Loss of Company Founder Dr. H.C. Peter Grogg
Bubendorf, Switzerland--(Newsfile Corp. - June 3, 2025) - The founder and honorary chairman of Bachem (SIX: BANB) Peter Grogg, passed away on Monday, June 2, 2025, at the age of 83. Peter Grogg founded Bachem in 1971 and built the company from a two-person operation into the global market leader for the chemical synthesis of peptides. Peter Grogg was CEO of the company for over 30 years until 2002 and Chairman of the Board of Directors of Bachem Holding AG until 2012. His daughter Nicole Grogg Hötzer has served as Vice-Chairwoman of the Board since 2011. For his achievements and merits in the field of peptides, Peter Grogg was awarded an honorary doctorate by the University of Basel. Kuno Sommer, Chairman of the Board of Directors of Bachem: "With Peter Grogg, we have lost a great entrepreneur. His drive and values made Bachem an internationally successful company and have left a lasting mark on it. In doing so, he has written a chapter of Swiss economic history. On behalf of the Board of Directors, the Executive Committee, and all employees of Bachem, I would like to express our deepest condolences to his wife, his two children, and their families." About Bachem Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and sites in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments. To view the source version of this press release, please visit
